Medicine and Dentistry
Cancer
100%
Oncologist
67%
Diseases
49%
Colorectal Carcinoma
35%
Symptomatic Treatment
35%
Metastatic Carcinoma
32%
Awareness
32%
Pathologist
31%
Melanoma
30%
Thyroid Cancer
25%
Neoplasm
23%
Overall Survival
23%
Papillary Thyroid Cancer
20%
Cytoreductive Surgery
19%
Immunotherapy
17%
Microbiome
17%
Rectum Cancer
17%
Hyperthermic Intraperitoneal Chemotherapy
16%
Surgery
15%
Neoadjuvant Therapy
15%
Malignant Neoplasm
15%
Surgeon
14%
Hazard Ratio
14%
Thyroid Nodule
13%
Adenocarcinoma
13%
Appendix Tumor
13%
Androgen Receptor
13%
Meta-Analysis
13%
Targeted Therapy
13%
Peritoneum Mesothelioma
13%
Recurrent Disease
13%
Retroperitoneal Lymph Node Dissection
12%
Lymph Node
11%
Carcinosis
11%
Intraperitoneal Chemotherapy
11%
Abdominal Cancer
11%
Gut
10%
Oncology
9%
Differentiated Thyroid Cancer
9%
Recurrence Free Survival
9%
Gastrointestinal Stromal Tumor
8%
Paraaortic Lymph Node
8%
Desmoplastic Small Round Cell Tumor
8%
Receptor Blocking
8%
Neuroendocrine Tumor
8%
Ovarian Tumor
8%
Cancer Survival
8%
Immune Checkpoint Blockade
8%
Pancreas Adenocarcinoma
8%
Fine-Needle Aspiration
7%
Keyphrases
Peritoneal Surface Malignancy
67%
Chicago
65%
Colorectal Cancer
35%
Radiologists
34%
Appropriate Management
32%
Enhanced Awareness
32%
Peritoneal Surface Disease
32%
Pharmacist
32%
Surgical Oncologist
32%
Pathologist
32%
Palliative Care Physicians
32%
Medical Oncologist
32%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
21%
Overall Survival
18%
Melanoma
16%
Thyroid Cancer
15%
Pathologic
15%
Cytoreductive Surgery
14%
Hazard Ratio
13%
Breast
13%
Appendiceal Neoplasms
13%
Appendiceal Adenocarcinoma
13%
Targeted Therapy
13%
Total Neoadjuvant Therapy
10%
Programmed Death-ligand 1 (PD-L1)
10%
Confidence Interval
9%
Resection
9%
Gastrointestinal Stromal Tumor
8%
Androgen Receptor Blockade
8%
Neuroendocrine Tumor
8%
Meta-analysis
8%
Optimizing Outcomes
8%
Para-aortic Lymph Node Dissection
8%
Lymph Node Positive
8%
Gastric Metastasis
8%
Colorectal Metastases
8%
Para-aortic Lymph Node
8%
Desmoplastic Small Round Cell Tumor (DSRCT)
8%
Ovarian Neoplasms
8%
Fucosylation
8%
Peritoneal Mesothelioma
8%
Recurrence-free Survival
8%
Carcinomatosis
7%
Clinical Factors
7%
Treatment Strategy
7%
Laparoscopic HIPEC
7%
Gastric Adenocarcinoma
6%
Gynecologic Oncologist
6%
Systemic Chemotherapy
6%
Gut Microbiome
5%